Pacira (PCRX)
NASDAQ:PCRX
PCRX Stock Chart & Stats
$23.25
-$0.08(-0.43%)
At close: 4:00 PM EST
$23.25
-$0.08(-0.43%)
Day’s Range― - ―
52-Week Range$18.80 - $27.64
Previous CloseN/A
Volume54.84K
Average Volume (3M)843.86K
Market Cap
$941.39M
Enterprise Value$1.30B
Total Cash (Recent Filing)$238.42M
Total Debt (Recent Filing)$454.38M
Price to Earnings (P/E)164.0
Beta0.83
Next Earnings
May 06, 2026EPS Estimate
0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.57
Shares Outstanding40,489,895
10 Day Avg. Volume494,895
30 Day Avg. Volume843,855
Financial Highlights & Ratios
PEG Ratio-1.53
Price to Book (P/B)1.66
Price to Sales (P/S)1.59
P/FCF Ratio8.44
Enterprise Value/Market Cap1.38
Enterprise Value/Revenue1.78
Enterprise Value/Gross Profit2.30
Enterprise Value/Ebitda10.65
Forecast
1Y Price Target
$27.50Price Target Upside18.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)2.65
Revenue Forecast (FY)$761.73M
Bulls Say, Bears Say
Bulls Say
Capital AllocationA sizable share repurchase program and remaining buyback authorization point to a shareholder-friendly capital allocation approach that can support earnings per share and investor returns.
Commercial Execution For ZilrettaA new partnership that rebuilt promotional capacity and a fully active sales force for Zilretta increases the likelihood of renewed sales momentum across target specialties.
Reimbursement And Commercial AccessExpanded commercial payer coverage and the NOPAIN initiative broaden patient access to Exparel, supporting continued volume gains as facilities adopt non-opioid pain protocols.
Bears Say
Competition And Reimbursement RiskPotential generic challengers and uncertainty in reimbursement policy for non-opioid treatments pose meaningful downside risk that could erode market share and revenue prospects.
Guidance And ExpectationsCompany guidance that sits below analyst consensus could trigger investor disappointment and pressure the stock if outlook assumptions are viewed as conservative.
Pricing Pressure And Product MixPrice discounting tied to a new group purchasing agreement and a shift toward different vial sizes has weighed on net pricing, limiting revenue growth despite higher shipment volumes.
Pacira Pharmaceuticals News
PCRX FAQ
What was Pacira’s price range in the past 12 months?
Pacira lowest stock price was $18.80 and its highest was $27.64 in the past 12 months.
What is Pacira’s market cap?
Pacira’s market cap is $941.39M.
When is Pacira’s upcoming earnings report date?
Pacira’s upcoming earnings report date is May 06, 2026 which is in 27 days.
How were Pacira’s earnings last quarter?
Pacira released its earnings results on Feb 26, 2026. The company reported $0.57 earnings per share for the quarter, missing the consensus estimate of $0.905 by -$0.335.
Is Pacira overvalued?
According to Wall Street analysts Pacira’s price is currently Undervalued.
Does Pacira pay dividends?
Pacira does not currently pay dividends.
What is Pacira’s EPS estimate?
Pacira’s EPS estimate is 0.56.
How many shares outstanding does Pacira have?
Pacira has 40,489,895 shares outstanding.
What happened to Pacira’s price movement after its last earnings report?
Pacira reported an EPS of $0.57 in its last earnings report, missing expectations of $0.905. Following the earnings report the stock price went down -3.01%.
Which hedge fund is a major shareholder of Pacira?
Currently, no hedge funds are holding shares in PCRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pacira Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.50 (18.28% Upside)
$27.50 (18.28% Upside)
Blogger Sentiment
Bullish
PCRX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 47.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.7%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.49%
12-Months-Change
Fundamentals
Return on Equity
0.95%
Trailing 12-Months
Asset Growth
-18.58%
Trailing 12-Months
Company Description
Pacira
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
PCRX Company Deck
PCRX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a broadly positive outlook: Pacira reported record gross margins, reinvigorated EXPAREL volume growth (~7% in Q4), expanded payer coverage (102M lives outside the bundle), strengthened IP (21 patents) and secured strategic partnerships (LG Chem, J&J). The company is investing in a promising pipeline (PCRX-201, PCRX-2002) and returned capital via buybacks while maintaining a healthy cash position ($238M). Offsetting items include rising R&D and SG&A (notably +56% R&D and +30% SG&A in Q4), revenue headwinds from buy-mix/discounting tied to a GPO, flat ZILRETTA sales, and near-term margin/inventory pressures. Overall, the positives (top-line momentum, margin expansion, IP runway, partnerships, and pipeline progress) outweigh the near-term cost and execution risks.View all PCRX earnings summariesPCRX Stock 12 Month Forecast
Average Price Target
$27.50
▲(18.28% Upside)
Technical Analysis
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Ownership Overview
3.69% Insiders
25.75% Mutual Funds
23.78% Other Institutional Investors
13.45% Public Companies and
Individual Investors